Evidence map›Paper›PMID 42830640›Full record

ArticleChemMedChem2026

Discrepancy in Reported and Observed Monoacylglycerol Lipase Inhibition of Aryl Formyl Piperidine Containing Potent and Highly Selective Monoacylglycerol Lipase Inhibitor.

Juha R Savinainen, Praveen Kumar Singh, Jari Yli-Kauhaluoma, Jayendra Z Patel

Abstract read
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Juha R SavinainenInstitute of Biomedicine, School of Medicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.ORCID https://orcid.org/0000-0002-1301-9064
Praveen Kumar SinghDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0009-0007-9832-487X
Jari Yli-KauhaluomaDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0003-0370-7653
Jayendra Z PatelDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0002-2562-1888

Funding

Academy of Finland 322724EDUFI funding TM-18-11003Tampereen Tuberkuloosisäätiö
6 · The paper itself

Abstract

Zhi et al. reported compound 36 as a potent reversible inhibitor of human recombinant monoacylglycerol lipase (hrMAGL; IC

Indexed as

Enzyme InhibitorsMonoacylglycerol LipasesPiperidinesAnimalsDose-Response Relationship, DrugHEK293 CellsHumansMiceMolecular StructureStructure-Activity RelationshipEnzyme InhibitorsMonoacylglycerol LipasesPiperidines2‐arachidonoyl glycerolinhibitorsmonoacylglycerol lipaseselective

Identifiers

PMID42830640
PMCPMC13635760

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.